Text Size:AAA

DLL4 / Delta-4 抗體, 鼠單抗

產品資料評論實驗方法
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10171-H08H-50
10171-H08H-100
50 µg 
100 µg 
Add to Cart
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10171-H02H-50
10171-H02H-100
50 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
  • Slide 1
10171-HCCH-50
10171-HCCH-200
50 µg 
200 µg 
Add to Cart
描述: Active  
表達宿主: Human Cells  
  • Slide 1
50640-M08H-50
50640-M08H-100
50 µg 
100 µg 
Add to Cart

DLL4/Delta-like 4 ELISA配對抗體

檢測限: 9.375 pg/ml
SEK50640-5
SEK50640-15
5 Plates 
15 Plates 
Add to Cart
檢測限: 31.25 pg/ml
SEK10171-5
SEK10171-15
5 Plates 
15 Plates 
Add to Cart

DLL4/Delta-like 4 AntibodyRelated Products

Related Products

Featured Reagent Products

DLL4/Delta-like 4 antibody 研究背景

Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

 DLL4/Delta-like 4 antibody 參考資料
  • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
  • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
  • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
  • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”